tiprankstipranks
Trending News
More News >
Precigen, Inc. (PGEN)
:PGEN
US Market

Precigen (PGEN) Stock Forecast & Price Target

Compare
989 Followers
See the Price Targets and Ratings of:

PGEN Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
5 Buy
0 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Precigen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PGEN Stock 12 Month Forecast

Average Price Target

$6.25
▲(316.67%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is $6.25 with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 316.67% change from the last price of $1.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,1.9692307692307693,2.3884615384615384,2.8076923076923075,3.226923076923077,3.6461538461538465,4.065384615384615,4.484615384615385,4.903846153846154,5.323076923076923,5.742307692307692,6.161538461538462,6.5807692307692305,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,1.9115384615384616,2.273076923076923,2.6346153846153846,2.996153846153846,3.3576923076923078,3.7192307692307693,4.0807692307692305,4.4423076923076925,4.803846153846154,5.165384615384616,5.526923076923077,5.888461538461538,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,1.8923076923076922,2.2346153846153847,2.5769230769230766,2.9192307692307695,3.2615384615384615,3.6038461538461535,3.9461538461538463,4.288461538461538,4.630769230769231,4.973076923076923,5.315384615384615,5.657692307692307,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.35,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.00Average Price Target$6.25Lowest Price Target$6.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PGEN
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
0.00%
Upside
Reiterated
06/07/25
Precigen faces significant financial hurdles with negative equity and ongoing losses, weighing heavily on its stock score. However, the promising outlook from the earnings call, including potential market entry for PRGN-2012 and strategic commercial preparations, provides a positive counterbalance, preventing a lower score.
J.P. Morgan Analyst forecast on PGEN
Brian ChengJ.P. Morgan
J.P. Morgan
Sell
Reiterated
05/19/25
J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)
H.C. Wainwright Analyst forecast on PGEN
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$6
Buy
300.00%
Upside
Reiterated
05/15/25
Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Adverum Biotechnologies (ADVM)
Citizens JMP Analyst forecast on PGEN
Jason ButlerCitizens JMP
Citizens JMP
$6
Buy
300.00%
Upside
Reiterated
05/15/25
Citizens JMP Sticks to Their Buy Rating for Precigen (PGEN)
Cantor Fitzgerald Analyst forecast on PGEN
Jennifer KimCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/15/25
Cantor Fitzgerald reiterates Overweight Rating on Precigen Inc. (PGEN)Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating on Precigen Inc. (NASDAQ: PGEN).
Stifel Nicolaus Analyst forecast on PGEN
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$7
Buy
366.67%
Upside
Reiterated
03/20/25
Analysts Offer Insights on Healthcare Companies: Precigen (NASDAQ: PGEN) and Edwards Lifesciences (NYSE: EW)
Citi
$6
Buy
300.00%
Upside
Reiterated
03/19/25
Precigen's Promising Outlook: Buy Rating Backed by Strategic Initiatives and PRGN-2012's Potential FDA Approval
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PGEN
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
0.00%
Upside
Reiterated
06/07/25
Precigen faces significant financial hurdles with negative equity and ongoing losses, weighing heavily on its stock score. However, the promising outlook from the earnings call, including potential market entry for PRGN-2012 and strategic commercial preparations, provides a positive counterbalance, preventing a lower score.
J.P. Morgan Analyst forecast on PGEN
Brian ChengJ.P. Morgan
J.P. Morgan
Sell
Reiterated
05/19/25
J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)
H.C. Wainwright Analyst forecast on PGEN
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$6
Buy
300.00%
Upside
Reiterated
05/15/25
Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Adverum Biotechnologies (ADVM)
Citizens JMP Analyst forecast on PGEN
Jason ButlerCitizens JMP
Citizens JMP
$6
Buy
300.00%
Upside
Reiterated
05/15/25
Citizens JMP Sticks to Their Buy Rating for Precigen (PGEN)
Cantor Fitzgerald Analyst forecast on PGEN
Jennifer KimCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/15/25
Cantor Fitzgerald reiterates Overweight Rating on Precigen Inc. (PGEN)Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating on Precigen Inc. (NASDAQ: PGEN).
Stifel Nicolaus Analyst forecast on PGEN
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$7
Buy
366.67%
Upside
Reiterated
03/20/25
Analysts Offer Insights on Healthcare Companies: Precigen (NASDAQ: PGEN) and Edwards Lifesciences (NYSE: EW)
Citi
$6
Buy
300.00%
Upside
Reiterated
03/19/25
Precigen's Promising Outlook: Buy Rating Backed by Strategic Initiatives and PRGN-2012's Potential FDA Approval
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Precigen

1 Month
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
-0.35%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of -0.35% per trade.
3 Months
xxx
Success Rate
13/27 ratings generated profit
48%
Average Return
+2.98%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.15% of your transactions generating a profit, with an average return of +2.98% per trade.
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
7/13 ratings generated profit
54%
Average Return
+7.25%
reiterated a buy rating 27 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +7.25% per trade.
2 Years
xxx
Success Rate
9/13 ratings generated profit
69%
Average Return
+14.05%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +14.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PGEN Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
9
6
5
8
8
Buy
1
1
1
1
2
Hold
0
0
0
0
0
Sell
1
0
0
0
1
Strong Sell
0
0
0
0
0
total
11
7
6
9
11
In the current month, PGEN has received 10 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. PGEN average Analyst price target in the past 3 months is 6.25.
Each month's total comprises the sum of three months' worth of ratings.

PGEN Financial Forecast

PGEN Earnings Forecast

Next quarter’s earnings estimate for PGEN is -$0.08 with a range of -$0.09 to -$0.08. The previous quarter’s EPS was -$0.18. PGEN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year PGEN has Preformed in-line its overall industry.
Next quarter’s earnings estimate for PGEN is -$0.08 with a range of -$0.09 to -$0.08. The previous quarter’s EPS was -$0.18. PGEN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year PGEN has Preformed in-line its overall industry.

PGEN Sales Forecast

Next quarter’s sales forecast for PGEN is $667.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $1.34M. PGEN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year PGEN has Outperformed its overall industry.
Next quarter’s sales forecast for PGEN is $667.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $1.34M. PGEN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year PGEN has Outperformed its overall industry.

PGEN Stock Forecast FAQ

What is PGEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Precigen, Inc.’s 12-month average price target is 6.25.
    What is PGEN’s upside potential, based on the analysts’ average price target?
    Precigen, Inc. has 316.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PGEN a Buy, Sell or Hold?
          Precigen, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Precigen, Inc.’s price target?
            The average price target for Precigen, Inc. is 6.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $7.00 ,the lowest forecast is $6.00. The average price target represents 316.67% Increase from the current price of $1.5.
              What do analysts say about Precigen, Inc.?
              Precigen, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of PGEN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis